Author: PWeekly
Long-acting antiretroviral therapy suppresses HIV among people with unstable housing, mental illnesses, substance use
NIH-supported study demonstrates injectable ART may improve outcomes in underserved patients A...
Read More
Obesity Medicine Opens 2023 With Important Advances
Announcements from the AMA and the AAP, plus innovative drug launches, are some of the major...
Read More
Every Physician Has a Role in Reducing Low-Value Care
Medicine and healthcare are complex. Often, patients hear from friends or family members regarding...
Read More
Zebras & CPR
In medical training, we are educated about a wide variety of medical conditions. Our training...
Read More
Anti-Science Words Don’t Hurt Science: They Just Hurt Us
As a child, I was taught that “sticks and stones could break my bones, but words could never harm...
Read More
Retinal Age: A Novel Biomarker for Incident ESKD
Prior research suggests that biological age, a measure of the body’s functional capability, is an...
Read More
For Acute Musculoskeletal Injury, MOVE, Not RICE
Approximately 30% of all visits to a primary care physician are for musculoskeletal issues, yet...
Read More
Prior Authorization Negative Impacts: By the Numbers
While many medical professionals like to give voice to their frustrations regarding prior...
Read More
Preventing & Treating Chronic Pain in Breast Cancer Survivors: Exploring Clinician Perceptions
Physical and psychosocial symptoms, such as pain, are common after breast cancer treatment is...
Read MoreMetabolic Tumor Volume Predicts Response to Loncastuximab Tesirine in DLBCL
Metabolic tumor volume (MTV) was reported at the 2022 annual meeting of the American Society of Hematology to be a predictive biomarker for patients with relapsed or refractory diffuse large B-cell lymphoma (rel/ref DLBCL) who...
Read More
Blinatumomab Candidate for Standard-of-Care in Newly Diagnosed B-ALL
measurable residual disease (MRD)-negative showed an overall survival (OS) benefit if they were...
Read More
Novel Therapy May Replace Standard-of-Care Prophylaxis for GVHD
Post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil outperformed...
Read More